Literature DB >> 9580597

Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes.

G Griffin1, P J Atkinson, V M Showalter, B R Martin, M E Abood.   

Abstract

Cannabinoid receptors are members of the superfamily of G protein-coupled receptors. Their activation has previously been shown to stimulate guanosine 5'-O-(3-[35S]thio)-triphosphate ([35S]GTP gamma S) binding in a range of brain regions using both membrane preparations and autoradiography. This study evaluates the activities of structurally diverse cannabinoid receptor ligands in the GTP gamma S binding assay, comparing the relationship between receptor binding and activation and also examining efficacy differences between compounds. Using rat cerebellar membrane preparations, the effects of GDP concentration on GTP gamma S binding and the activities of a range of cannabinoid receptor ligands, including the CB1 selective antagonist SR141716A, were investigated. GDP concentration was found to have differing effects on cannabinoid-stimulated [35S]GTP gamma S binding depending on the nature of the agonist used. The stimulation produced by high efficacy compounds, such as CP 55,940 and WIN 55212-2, was increased by raising the GDP concentration, but that of a low efficacy agonist, (-)-delta-tetrahydrocannabinol, was decreased. Of the cannabinoid compounds tested, a wide range of potencies (EC50) and levels of maximal stimulation (Emax) were observed. These ranged from CP 55,244 (Emax of 165, 148-183%, and an EC50 of 0.47, 0.22-0.96, nM) through (-)-delta-tetrahydrocannabinol, cannabinol and anandamide, which produced no concentration-dependent stimulation of [35S]GTP gamma S binding under the same conditions. SR141716A competitively antagonized all the agonists against which it was tested, providing equilibrium dissociation constants (Kd values) in the sub-nanomolar range (0.06-0.40 nM), implicating a CB1 receptor mediated response. These results provide a more detailed characterization of the cannabinoid-stimulated [35S]GTP gamma S binding assay than has previously been reported.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9580597

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  39 in total

Review 1.  Efficacy in CB1 receptor-mediated signal transduction.

Authors:  Allyn C Howlett
Journal:  Br J Pharmacol       Date:  2004-08       Impact factor: 8.739

2.  Role of different brain structures in the behavioural expression of WIN 55,212-2 withdrawal in mice.

Authors:  Anna Castañé; Rafael Maldonado; Olga Valverde
Journal:  Br J Pharmacol       Date:  2004-07-20       Impact factor: 8.739

3.  Thermolytic Degradation of Synthetic Cannabinoids: Chemical Exposures and Pharmacological Consequences.

Authors:  Brian F Thomas; Timothy W Lefever; Ricardo A Cortes; Megan Grabenauer; Alexander L Kovach; Anderson O Cox; Purvi R Patel; Gerald T Pollard; Julie A Marusich; Richard C Kevin; Thomas F Gamage; Jenny L Wiley
Journal:  J Pharmacol Exp Ther       Date:  2017-01-13       Impact factor: 4.030

Review 4.  Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?

Authors:  William E Fantegrossi; Jeffery H Moran; Anna Radominska-Pandya; Paul L Prather
Journal:  Life Sci       Date:  2013-09-29       Impact factor: 5.037

5.  Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs.

Authors:  Lirit N Franks; Benjamin M Ford; Nikhil R Madadi; Narsimha R Penthala; Peter A Crooks; Paul L Prather
Journal:  Eur J Pharmacol       Date:  2014-05-20       Impact factor: 4.432

Review 6.  Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites.

Authors:  Sherrica Tai; William E Fantegrossi
Journal:  Curr Top Behav Neurosci       Date:  2017

7.  Separation of cannabinoid receptor affinity and efficacy in delta-8-tetrahydrocannabinol side-chain analogues.

Authors:  G Griffin; S Williams; M M Aung; R K Razdan; B R Martin; M E Abood
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

8.  Mouse Neuroblastoma CB1 Cannabinoid Receptor-Stimulated [35S]GTPɣS Binding: Total and Antibody-Targeted Gα Protein-Specific Scintillation Proximity Assays.

Authors:  Khalil Eldeeb; Sandra Leone-Kabler; Allyn C Howlett
Journal:  Methods Enzymol       Date:  2017-07-19       Impact factor: 1.600

9.  Pharmacological characterization of repeated administration of the first generation abused synthetic cannabinoid CP47,497.

Authors:  Travis W Grim; Kimberly L Samano; Bogna Ignatowska-Jankowska; Qing Tao; Laura J Sim-Selly; Dana E Selley; Laura E Wise; Alphonse Poklis; Aron H Lichtman
Journal:  J Basic Clin Physiol Pharmacol       Date:  2016-05-01

10.  Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells.

Authors:  Sean D McAllister; Calvin Chan; Ryan J Taft; Tri Luu; Mary E Abood; Dan H Moore; Ken Aldape; Garret Yount
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.